Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences.

Davydov DR, Davydova NY, Rodgers JT, Rushmore TH, Jones JP.

Biochem J. 2017 Oct 10;474(20):3523-3542. doi: 10.1042/BCJ20170543.

2.

Discovery of selective glucocorticoid receptor modulator MK-5932.

Bungard CJ, Hartman GD, Manikowski JJ, Perkins JJ, Bai C, Brandish PE, Euler DH, Hershey JC, Schmidt A, Fang Y, Norcross RT, Rushmore TH, Thompson CD, Meissner RS.

Bioorg Med Chem. 2011 Dec 15;19(24):7374-86. doi: 10.1016/j.bmc.2011.10.054. Epub 2011 Oct 24.

PMID:
22079253
3.

Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Frederick DM, Jacinto EY, Patel NN, Rushmore TH, Tchao R, Harvison PJ.

Toxicol In Vitro. 2011 Dec;25(8):2113-9. doi: 10.1016/j.tiv.2011.09.015. Epub 2011 Sep 22.

4.

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY.

Genome Res. 2010 Aug;20(8):1020-36. doi: 10.1101/gr.103341.109. Epub 2010 Jun 10.

5.

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M.

Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11.

PMID:
19279563
6.

Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues.

Peng CC, Cape JL, Rushmore T, Crouch GJ, Jones JP.

J Med Chem. 2008 Dec 25;51(24):8000-11. doi: 10.1021/jm8011257.

7.

Mapping the genetic architecture of gene expression in human liver.

Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Johnson JM, Rohl CA, van Nas A, Mehrabian M, Drake TA, Lusis AJ, Smith RC, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich R.

PLoS Biol. 2008 May 6;6(5):e107. doi: 10.1371/journal.pbio.0060107.

8.

CYP2C75-involved autoinduction of metabolism in rhesus monkeys of methyl 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-carboxylate (MK-0686), a bradykinin B1 receptor antagonist.

Tang C, Carr BA, Poignant F, Ma B, Polsky-Fisher SL, Kuo Y, Strong-Basalyga K, Norcross A, Richards K, Eisenhandler R, Carlini EJ, Di Marco CN, Kuduk SD, Yu NX, Raab CE, Rushmore T, Frederick CB, Bock MG, Prueksaritanont T.

J Pharmacol Exp Ther. 2008 Jun;325(3):935-46. doi: 10.1124/jpet.107.136044. Epub 2008 Feb 29.

PMID:
18310472
9.

Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.

Peng CC, Rushmore T, Crouch GJ, Jones JP.

Bioorg Med Chem. 2008 Apr 1;16(7):4064-74. doi: 10.1016/j.bmc.2008.01.021. Epub 2008 Jan 18.

PMID:
18255300
10.

Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors.

Tang C, Fang Y, Booth-Genthe C, Kuo Y, Kuduk SD, Rushmore TH, Carr BA.

Biochem Pharmacol. 2007 Mar 15;73(6):880-90. Epub 2006 Nov 25.

PMID:
17223083
11.

Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome.

Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, Cheng OJ, Caguyong M, Ulrich RG.

Xenobiotica. 2006 Oct-Nov;36(10-11):938-62.

PMID:
17118915
12.

Microarray-based compendium of hepatic gene expression profiles for prototypical ADME gene-inducing compounds in rats and mice in vivo.

Slatter JG, Cheng O, Cornwell PD, de Souza A, Rockett J, Rushmore T, Hartley D, Evers R, He Y, Dai X, Hu R, Caguyong M, Roberts CJ, Castle J, Ulrich RG.

Xenobiotica. 2006 Oct-Nov;36(10-11):902-37.

PMID:
17118914
13.

Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.

Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, Booth-Genthe C.

Drug Metab Dispos. 2006 Oct;34(10):1703-12. Epub 2006 Jun 30.

PMID:
16815964
14.

Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.

Li SX, Pequignot E, Panebianco D, Lupinacci P, Majumdar A, Rosen L, Ahmed T, Royalty JE, Rushmore TH, Murphy MG, Petty KJ.

J Clin Pharmacol. 2006 Jul;46(7):792-801.

PMID:
16809805
15.

Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.

Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, Yamazaki M.

J Pharmacol Toxicol Methods. 2006 Jul-Aug;54(1):78-89. Epub 2006 Mar 20.

PMID:
16545584
16.

Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activity.

Gibson CR, Lin C, Singh R, Brown CM, Richards K, Brunner J, Michel K, Adelsberger J, Carlini E, Boothe-Genthe C, Raab C, Luu M, Michael A, Parikh M, Ciecko P, Subramanian R, Krolikowski P, Rodrigues AD, Baillie TA, Rushmore TH.

Drug Metab Dispos. 2005 Jul;33(7):1044-51. Epub 2005 Apr 15.

PMID:
15833927
17.

Selective inhibition of dog hepatic CYP2B11 and CYP3A12.

Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M.

J Pharmacol Exp Ther. 2005 May;313(2):518-28. Epub 2005 Jan 26.

PMID:
15677349
18.

Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol.

Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD.

Drug Metab Dispos. 2004 Nov;32(11):1299-303.

PMID:
15483196
19.

Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection.

Chen Q, Tan E, Strauss JR, Zhang Z, Fenyk-Melody JE, Booth-Genthe C, Rushmore TH, Stearns RA, Evans DC, Baillie TA, Tang W.

J Pharmacol Exp Ther. 2004 Oct;311(1):307-14. Epub 2004 May 26.

PMID:
15163679
20.

Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression.

Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, Evans DC.

Mol Pharmacol. 2004 May;65(5):1159-71.

PMID:
15102944
21.

Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450.

Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH, Prough RA.

Drug Metab Dispos. 2004 Mar;32(3):305-13.

PMID:
14977864
22.

Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450.

Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH.

Drug Metab Dispos. 2003 Sep;31(9):1161-9.

PMID:
12920172
23.

Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.

Rushmore TH, Kong AN.

Curr Drug Metab. 2002 Oct;3(5):481-90. Review.

PMID:
12369894
24.

Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.

Rodrigues AD, Rushmore TH.

Curr Drug Metab. 2002 Jun;3(3):289-309. Review. Erratum in: Curr Drug Metab. 2002 Oct;3(5):559..

PMID:
12083322
25.

Inhibition kinetics of monoclonal antibodies against cytochromes P450.

Mei Q, Tang C, Lin Y, Rushmore TH, Shou M.

Drug Metab Dispos. 2002 Jun;30(6):701-8.

PMID:
12019198
26.

Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4.

Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, Shou M.

Drug Metab Dispos. 2001 Nov;29(11):1473-9.

PMID:
11602524
27.

Enzyme kinetics of cytochrome P450-mediated reactions.

Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH.

Curr Drug Metab. 2001 Mar;2(1):17-36. Review.

PMID:
11465149
28.

An invasive cleavage assay for direct quantitation of specific RNAs.

Eis PS, Olson MC, Takova T, Curtis ML, Olson SM, Vener TI, Ip HS, Vedvik KL, Bartholomay CT, Allawi HT, Ma WP, Hall JG, Morin MD, Rushmore TH, Lyamichev VI, Kwiatkowski RW.

Nat Biotechnol. 2001 Jul;19(7):673-6. Erratum in: Nat Biotechnol 2002 Mar;20(3):307.

PMID:
11433281
29.

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD.

Pharmacogenetics. 2001 Apr;11(3):223-35.

PMID:
11337938
30.

Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays.

Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T.

Physiol Genomics. 2001 Apr 27;5(4):161-70.

PMID:
11328961
31.

Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility.

Bourdi M, Amouzadeh HR, Rushmore TH, Martin JL, Pohl LR.

Chem Res Toxicol. 2001 Apr;14(4):362-70.

PMID:
11304124
32.

Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.

Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74.

PMID:
11259318
33.

A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4.

Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH.

J Biol Chem. 2001 Jan 19;276(3):2256-62. Epub 2000 Oct 27.

34.

Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites.

Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M.

Metab Eng. 2000 Apr;2(2):115-25.

PMID:
10935727
35.

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.

Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD.

J Pharmacol Exp Ther. 2000 May;293(2):453-9.

PMID:
10773015
36.

Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.

Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 2000 Apr 18;39(15):4276-87.

PMID:
10757976
37.

Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.

Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, Shou M.

J Pharmacol Exp Ther. 1999 Nov;291(2):749-59.

PMID:
10525096
38.
39.

DNA chips: promising toys have become powerful tools.

Gerhold D, Rushmore T, Caskey CT.

Trends Biochem Sci. 1999 May;24(5):168-73. Review.

PMID:
10322428
40.

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.

McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR.

Clin Pharmacol Ther. 1999 Mar;65(3):348-52. No abstract available.

PMID:
10096267
41.

Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites.

Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR, Kwei GY, Rushmore TH, Chiu SH, Baillie TA.

Drug Metab Dispos. 1999 Mar;27(3):365-72.

PMID:
10064567
42.

Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 1999 Feb 23;38(8):2312-9.

PMID:
10029524
43.

Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms.

Wang RW, Newton DJ, Liu NY, Shou M, Rushmore T, Lu AY.

Drug Metab Dispos. 1999 Feb;27(2):167-72.

PMID:
9929498
44.

Refinement of an in vitro cell model for cytochrome P450 induction.

Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, Yergey JA, Nicoll-Griffith DA.

Drug Metab Dispos. 1998 May;26(5):490-6.

PMID:
9571231
45.
46.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
47.

Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents.

Fei P, Matwyshyn GA, Rushmore TH, Kong AN.

Pharm Res. 1996 Jul;13(7):1043-8.

PMID:
8842042
48.

Human prostanoid receptors: cloning and characterization.

Abramovitz M, Adam M, Boie Y, Grygorczyk R, Rushmore TH, Nguyen T, Funk CD, Bastien L, Sawyer N, Rochette C, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:499-504. No abstract available.

PMID:
7732897
49.

Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.

Cribb AE, Griffin GP, Spielberg SP, Rushmore TH, Chauret N, Nicoll-Griffith DA.

Drug Metab Dispos. 1994 Nov-Dec;22(6):969-72. No abstract available.

PMID:
7895617

Supplemental Content

Loading ...
Support Center